摘要
目的:通过对罗沙司他治疗肾性贫血有效性、安全性和经济性的快速卫生技术评估,为临床合理用药提供循证证据。方法:检索the Cochrane Library、PubMed、中国知网和万方数据库,纳入罗沙司他治疗肾性贫血的相关卫生技术评估报告、系统评价/Meta分析和药物经济性研究,检索时间为建库至2021年10月。由2名评价者独立根据纳入与排除标准筛选文献、评价文献质量并进行分析。结果:共纳入11篇系统评价/Meta分析和2篇药物经济学研究。结果显示,有效性方面,与安慰剂或对照药物比较,罗沙司他可明显升高肾性贫血患者的血红蛋白水平和总铁结合力,降低铁调素水平;安全性方面,使用罗沙司他治疗的患者不良事件和严重不良事件无明显增加,但高钾血症的发生率明显高于安慰剂组;经济性方面,罗沙司他用于非透析肾性贫血患者,有一定的成本-效用优势。结论:罗沙司他治疗肾性贫血具有良好的有效性和经济性,使用过程中应注意监测血钾浓度。
OBJECTIVE: To evaluate the efficacy, safety and economy of roxadustat in the treatment of renal anemia by rapid health technology, and to provide evidence-based evidence for clinical rational drug use. METHODS: The Cochrane Library, PubMed, CNKI and Wanfang Data were retrieved to collect the health technology assessment report, systematic evaluation/Meta-analysis and pharmacoeconomic study related to roxadustat in the treatment of renal anemia, the search time was from the establishment of the database to Oct. 2021. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, evaluated the quality of the literature, and analyzed the literature. RESULTS: Totally 11 systematic reviews/Meta-analysis and 2 pharmacoeconomic studies were included. In terms of efficacy, compared with placebo or control drugs, roxadustat could significantly increase the hemoglobin level and total iron binding capacity and decrease the hepcidin level in patients with renal anemia. In terms of safety, there was no significant increase in adverse events and severe adverse events in patients treated with roxadustat, yet the incidence of hyperkalemia was significantly higher than that in the placebo group. Economically, there was a cost-utility advantage to roxadustat for non-dialysis renal anemia patients. CONCLUSIONS: Rosarostat is effective and economical in the treatment of renal anemia, and care should be taken to monitor the serum potassium ion concentration.
作者
陈静
成华
李亚利
刘洋
孙文芳
庞晶瑶
刘宪军
CHEN Jing;CHENG Hua;LI Yali;LIU Yang;SUN Wenfang;PANG Jingyao;LIU Xianjun(Dept.of Pharmacy,Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China)
出处
《中国医院用药评价与分析》
2022年第10期1224-1227,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
首都临床特色应用研究项目(No.Z181100001718144)
北京市通州区科委基金项目(No.KJ2021CX008-37)。
关键词
罗沙司他
肾性贫血
快速卫生技术评估
Roxadustat
Renal anemia
Rapid health technology assessment
